Axsome Therapeutics Sees 58% YTD Gain, Analysts Predict Profit Ahead.

miércoles, 5 de noviembre de 2025, 2:11 pm ET1 min de lectura
AXSM--

Axsome Therapeutics (AXSM) is a biopharmaceutical developer for CNS conditions, including depression treatment. The stock is near an all-time high and in a buy zone, having climbed 58% this year and outperforming 87% of tracked stocks. Analysts see profit on the horizon for the company.

Axsome Therapeutics Sees 58% YTD Gain, Analysts Predict Profit Ahead.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios